1006899-48-4

Upstream product

• 541-16-2 t-butyl malonate 
• 586-78-7 para-nitrophenyl bromide 
• 278791-31-4 di-t-butyl 2-(4-nitrophenyl)malonate 
• 74-88-4 methyl iodide 

Downstream Products

• 1006950-22-6 di-tert-butyl 2-(4-aminophenyl)-2-methylmalonate hydrochloride 
• 1350651-06-7 di-tert-butyl 2-(4-(8-methoxy-8-oxooctanamido)phenyl)-2-methylmalonate 
• 1350651-08-9 methyl 8-(4-(2-methyl-1,3-dioxo-1,3-bis(quinolin-8-ylamino)propan-2-yl)phenylamino)-8-oxooctanoate 
• 1350651-10-3 methyl 8-oxo-8-(4-(1-oxo-1-(quinolin-8-ylamino)propan-2-yl)phenylamino)octanoate 
• 1350651-12-5 N₁-hydroxy-N₈-(4-(1-oxo-1-(quinolin-8-ylamino)propan-2-yl)phenyl)octanediamide 
• 1350651-14-7 N₁-hydroxy-N₈-(4-(2-methyl-1,3-dioxo-1,3-bis(quinolin-8-ylamino)propan-2-yl)phenyl)octanediamide 

Relevant academic research and scientific papers

SELECTIVE HDAC INHIBITORS

This disclosure is related to compounds having the structure (I) wherein Ar1, Ar2, R1 - R6, Z, m, n, o, and p are defined herein. This disclosure also relates to pharmaceutical compositions comprising the above compounds and methods for their use.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.